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Defi  ning the problem
Rheumatic diseases and malignant diseases sometimes 
occur in the same patient, either sequentially or simul  ta-
neously. Th   is can be by coincidence, but it is also estab-
lished that many of the systemic inﬂ  ammatory diseases, 
such as rheumatoid arthritis (RA), Sjögren syndrome, or 
systemic lupus erythematosus, per se increase the risk of 
malignant disease. Nevertheless, when rheumatic and 
malignant diseases occur in the same patient, this usually 
poses a therapeutic challenge to either the rheumatologist 
or the oncologist, depending on which of the two 
problems dominates in a given patient. In this review, we 
want to address the speciﬁ  c situation of a patient who has 
cancer or a history of cancer and who presents to the 
rheumatologist with a severe rheumatic condition that 
requires immunomodulation or immunosuppression.
Th   e initial question of the possible temporal and causal 
associations that possibly lead to this clinical situation 
arises. In principal, a healthy individual can develop a 
malig  nancy and subsequently a rheumatic disease simply 
by natural causes (Figure 1, arrow 1). Potentially, the 
treat  ment of the malignant disease may cause the 
rheumatic complaints (Figure 1, arrow 5) and, in theory, 
could also support the treatment of the rheumatic condi-
tion (Figure 1, arrow 6).
Is it safe to use immuno  suppressive drugs to treat a 
rheumatic patient with a (past) malignancy? At least
some concern arises from the fact (or myth?) that some 
of these drugs have a potential to induce or promote a 
malignant disease (Figure 1, arrow 3). In the literature, 
however, this issue is very diﬃ     cult to assess and is always 
overshadowed by the fact that some of the rheumatic 
entities have a per se increased risk for developing a 
malignant disease (Figure 1, arrow 2). Potentially, anti-
rheumatic treatment may also serve to control a 
malignant disease (for example, rituximab may be used to 
treat lymphoma) (Figure 1, arrow 4). Th   ere is a large body 
of literature exploring the risk of malignancy in treated or 
untreated RA. Th   e main purpose of this review, however, 
is to summarize the evidence that may help resolve the 
clinically problematic scenario of immunosuppressive 
therapy for rheumatic patients with a history of cancer. 
Th   e logical clinical outcome to evaluate for this purpose 
is the rate of cancer reactivation. As we will see, the 
direct evidence is scarce, and we will need to look at 
neigh boring  ﬁ  elds, especially the transplantation litera-
ture, to further explore the risk of cancer reactivation 
upon immunosuppressive treatment at a later stage.
For the sake of simplicity, we wish to exclude anti-
inﬂ   am  matory drugs and analgesics from our 
consideration and to focus on RA as the most prevalent 
inﬂ   ammatory rheumatic condition. However, before 
looking at the respective direct and indirect evidence, we 
must understand the risk of cancer per se (that is, in 
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the diﬀ  erent drugs used.
I    mmunosuppressive therapy and the development 
of malignancies in patients without prior 
malignancy
Carcinogenesis and lymphomagenesis are complex pro-
cesses involving genetic modulation and deregulation of 
the inﬂ  ammatory response, causing a resistance to apop-
tosis, unrestricted proliferation, increased angiogenesis, 
eventual invasion of blood and lymphatic vessels, and 
metastasis. In the past, immunosuppressive drugs have 
been blamed for promoting these processes by leading to 
a general downregulation of the immune system (impair-
ment of tumor surveillance) or increasing the suscepti-
bility to infection with oncogenic agents. For some others, 
speciﬁ   c mechanisms (for example, the direct pharma-
cologic alteration of DNA) have led to these concerns.
Aside from these general concepts of tumorigenesis, 
the question of whether (and to what extent) there are 
diﬀ  erences in the risk of malignancy following diﬀ  erent 
drugs arises. In the following, we will brieﬂ  y mention 
each of the relevant regimens. Figure 2 gives an overview 
of the semiquantitative assessment of the cancer risk of 
speciﬁ  c drugs on the basis of the literature. Th   ese risks of 
malignancy in patients without a tumor might be an 
initial point of consideration and give some guidance 
when planning to treat a patient with (a history of) a 
malignant disease.
Glucocorticoids
Th   e pleiotropic immunosuppressive eﬀ  ects of gluco  corti-
coids are the basis for the assumption that their use may 
promote immune-related cancers. Most of the commonly 
found associations of malignancies with (dosage and 
duration of) gluco  corticoid treatment relate to basal cell 
carcinoma, squamous cell carcinoma, non-Hodgkin lym-
phoma, and malignant melanoma [1-3].
On the other hand, some studies have questioned 
whether these associations were causal [4,5]. In the 
context of rheumatic diseases, it therefore remains 
entirely unclear whether a signiﬁ  cant risk of cancer is 
related to the underlying systemic disease, other immuno-
suppressive agents, and their combination or to the 
glucocorticoids per se. Nevertheless, the discordance of 
data in the literature might indicate that glucocorticoids 
at least do not carry a very high risk of malignancy and 
that they might be relatively safe regarding solid organ 
tumors, especially if used in reasonable doses and for 
limited periods of time.
Methotrexate
Methotrexate is one of the most important anti-
rheumatic regimens and has the least evidence regarding 
a potentially increased malignancy risk. Th  is has been 
demonstrated in cohorts with a variety of diseases. For 
incident cancers, it is again not clear whether this reﬂ  ects 
the disease per se or the treatment with methotrexate, 
which is often used to treat persistent active 
Figure 1. Temporal and causal associations between rheumatic and malignant diseases. A detailed description is presented in the ‘Defi  ning 
the problem’ section.
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in some cases, cancer was reversible after the 
discontinuation of methotrexate. Th   ere are reports of an 
increased risk of a post-transplant lymphoproliferative 
disorder-like (PTLD-like) condition in patients treated 
with methotrexate [6,7].
Other traditional disease-modifying anti-rheumatic drugs
Other traditional disease-modifying anti-rheumatic drugs 
(DMARDs) include sulfasalazine, (hydroxy-)chloroquine, 
and leﬂ  unomide. Sulfasalazine has even been postulated 
as chemo-prevention of colorectal cancer in patients with 
colitis ulcerosa [8]. On several cell lines, sulfasalazine has 
also shown anti-tumor activity in vitro [9], but a clinically 
relevant eﬀ  ect in vivo has not yet been shown. Available 
data regarding the carcinogenetic potential of 
chloroquine and hydroxychloroquine are limited and 
include a long-term observation in rats, in which no 
evidence of an association with cancer could be estab-
lished. For leﬂ  unomide, explicit human data are currently 
not available, but animal studies, such as those in rats, 
also detected no carcinogenetic potential.
Biologics
Biologics are a novel substance group with wide use in 
rheumatic and inﬂ   ammatory diseases. Th  ey interfere 
with cytokine signal  ing through various interactions with 
the cytokines and their receptors. A meta-analysis of 
5,014 patients of randomized controlled clinical trials in 
RA has found an increased risk of malignancy with 
monoclonal antibody tumor necrosis factor (TNF) 
inhibitors (while etanercept was excluded from their 
analysis) (odds ratio (OR) 2.4, 95% conﬁ  dence interval 
(CI) 1.2 to 4.8) [10] but has been questioned by many for 
various design and analysis issues. Also, this study 
contradicts seven large observa  tional studies of 
thousands of RA patients followed for a long time; those 
studies all found no increased overall cancer risk with 
anti-TNF agents. Askling and colleagues [11] reported a 
decreased relative risk of colorectal (−25%) and breast 
(−20%) cancer in patients with RA treated with TNF 
blockers. One of the studies, by Wolfe and Michaud [12], 
observed a higher risk for non-melanoma skin cancer 
(OR 1.5, 95% CI 1.2 to 1.8). Data from the Crohn disease 
cohort also found no increased risk of malignancy with 
TNF inhibitors (OR 1.33, 95% CI 0.46 to 3.84). 
Nevertheless, TNF inhibitors may accelerate the 
diagnosis of cancer in the ﬁ   rst 6 to 12  months of 
treatment but probably do not increase long-term cancer 
risk [10-26]. A potentially severe inter  action between 
alkylating drugs and TNF inhibitors was revealed in a 
randomized, controlled trial in which etanercept versus 
placebo in addition to conventional therapy for Wegener 
granulomatosis was evaluated and in which an excess 
occurrence of solid tumors was observed (standardized 
incidence ratio 3.12, 95% CI 1.15 to 6.80) [14].
In these large-scale long-term data on the use of TNF 
inhibitors from diﬀ  erent registries, the risk of induction 
of a malignant disease by these drugs appears to be 
relatively low though still controversial. Th  e lack of 
clearly consistent ﬁ   ndings, however, might also be an 
indicator that such a risk, if it exists, will likely be low and 
of questionable clinical relevance. Th   ere are currently too 
few data to investigate newer TNF inhibitors, such as 
golimumab and certolizumab, or biologics with other 
modes of action, such as abatacept and tocilizumab. 
Rituximab, a monoclonal antibody against anti-CD20, is 
itself used in treatment for malignant lymphoma and 
PTLD. Little is known about its risk of secondary 
malignancies in patients with RA.
Alkylating agents
In rheumatology, this group of immunosuppressants, the 
classical ‘chemotherapies’, is reserved for treatment of 
patients with severe organ involvement, usually of 
connective tissue disease or vasculitis. Alkylating agents 
increase the risk of hematologic malignancy, and 
Figure 2. Semiquantitative assessment of malignancy risk 
associated with specifi  c drugs. Red boxes indicate evidence 
for increased risk, yellow boxes indicate potential risk, and green 
boxes indicate little risk; blank boxes indicate that evidence is 
currently insuffi   cient to determine risk. PLTD-like, post-transplant 
lymphoproliferative disorder-like; TNF, tumor necrosis factor.
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Page 3 of 11cyclo  phosphamide, in particular, increases the incidence 
of bladder cancer [27-30]. Th   e increased risk of 
malignancy under cyclophosphamide therapy may not be 
evident until several years after treatment (5% at 10 years 
and 16% at 15 years) [30]. Little evidence exists for 
chlorambucil, even in the transplantation literature. 
Similarly to cyclo  phosphamide, it has been associated 
with a substantially higher rate of secondary hematologic 
neoplasm (in patients treated for malignancies), and 
leukemia may even be seen more frequently than with 
cyclophos  phamide [31]. In addition, a small study of 
chlorambucil in RA found that 21% of patients developed 
cutaneous neoplasia (mostly squamous cell carcinoma).
In summary, alkylating agents increase the risk of 
secondary hematologic malignancies, but as high-pulse 
doses of alkylating agents are used for treatment of 
hematologic malignancies, they might occasionally even 
serve the treatment of both conditions in a single patient. 
A broad spectrum of malignancies, such as might be 
expected if induction of mutation were the prevailing 
oncogenic mechanism, was not described for these 
agents [30], but caution needs to be taken in patients 
with a history of skin cancer or urogenital cancer (when 
cyclophosphamide is considered).
Calcineurin inhibitors
Cyclosporine and tacrolimus are less frequently used for 
the treatment of rheumatic diseases in the recent past but 
do not seem to increase cancer risk to a detectable degree 
in patients with an inﬂ  ammatory disease such as RA [32]. 
However, appreciation of the transplant literature calls 
for caution if these drugs are used in combination with 
glucocorticoids or other immunosuppressants (or both) 
in patients with a malignant disease or a history of one, 
although the role of cyclosporine itself remains unclear 
[32-37].
Anti-metabolites
Anti-metabolites, such as azathioprine, showed no signi-
ﬁ     cant increase in the risk of cancer development in 
patients with inﬂ   ammatory disease [38-41]. A case 
control study in multiple sclerosis patients with and 
without cancer found no association with azathioprine 
exposure [40]. In contrast, transplant patients treated 
with azathioprine, compared with the general population, 
probably do have an increased risk of malignancy, includ-
ing squamous cell carcinoma of the skin and lymphoid 
malignancies (Hodgkin and non-Hodgkin lymphoma) 
[42,43]. Again, the combi  na  tion immunosuppressive 
therapy makes it diﬃ   cult to assess true causality.
Mycophenolate mofetil
Mycophenolate mofetil is one of the newer drugs 
typically used in transplantation. Observational trials of 
mycophenolate have found a signiﬁ  cantly and sub  stan-
tially reduced risk of PTLDs, a lower risk of malignancy 
in general, and an improvement of survival in this patient 
population in comparison with alternative drugs, like 
azathioprine, cyclosporine, tacrolimus, or their combi-
nations [42-47].
Rapamycin
Th  ough not used to treat rheumatologic disorders, 
rapamycin (inhibitor of mammalian target of rapamycin, 
or mTOR) is worth noting in this review. It is an immuno-
suppressive agent with anti-oncogenic properties and 
therefore might be an immunosuppressive treatment 
option to be considered and investigated for patients who 
have rheumatic disorders and who are at risk for or have 
a history of cancer [48-50].
Direct evidence on the risk of immunosuppressive 
therapy of patients with current or past 
malignancy
Data from the fi  eld of rheumatology
Th  e very topic of this review is the safety of immuno-
suppressants in rheumatic patients who have a history of 
malignant disease. To identify evidence in this ﬁ  eld, we 
performed a literature search of Medline, Embase, and 
the Cochrane database by using terms that deﬁ  ne the 
various inﬂ  ammatory rheumatic diseases and combining 
these with the term ‘malignancy’ and its synonyms. In 
total, two studies investigated the risk of cancer 
recurrence in rheumatic patients; all others were 
addressing either the risk of cancer associated with the 
respective rheumatic condition or its treatment in 
patients without a history of cancer (or both).
Th  e  ﬁ  rst study, a prospective observational study using 
data from the British Society for Rheumatology Biologics 
Register, identiﬁ  ed 293 patients with prior malignancy 
from more than 14,000 patients with RA [51]. Prior non-
melanoma skin cancers were excluded. Th   e overall cancer 
incidence in this population was evaluated in patients 
who were then exposed to TNF inhibitors (n = 177) or 
traditional DMARDs (n = 117). In summary, the rate of 
incident malignancy was numerically even lower in the 
TNF inhibitor group, but selection bias needs to be 
considered (patients with a high risk of relapse are more 
likely to be treated with traditional DMARDs). Only one 
patient developed a local recurrence; all other tumors 
were  de novo. Interestingly, among patients with prior 
melanoma, 3 out of 17 in the TNF inhibitor group 
developed an incident malignancy (of any kind) whereas 
0 out of 10 in the DMARD group did so.
Th  e second study was similarly based on a national 
register, the German RABBIT (German acronym for 
Rheumatoid Arthritis – Observation of Biologic Th  erapy) 
register, in which 122 patients with a prior malignancy 
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122 patients showed no signiﬁ  cant increase in the risk of 
relapse on TNF inhibitor therapy compared with 
conventional DMARD therapy [52]. Interestingly, in 
contrast to the British study, 14 of the 15 recurrent 
cancers were of the same type and site as the prior tumor. 
Th   e authors did not ﬁ  nd any signal toward an increased 
risk of recurrence on TNF inhibitor treat  ment compared 
with traditional DMARDs; but, again, the results of this 
study were limited by the small number of events.
In summary, these two articles on the exact topic of 
this review were published very recently. Th  ey are both 
observational, based on registry data, and therefore not 
randomized. Th   e two major problems of these studies are 
selection bias and low incidence of the outcomes: in the 
British register, the time since malignancy was far longer 
in those patients treated with anti-TNF than in the 
control group and in total longer than in the German 
register. A considerable proportion of the German 
patients (equally in the anti-TNF and the control groups) 
was treated within a time window during which 
recurrences have to be expected. Nevertheless, the design 
of these studies is potentially the best direct evidence one 
can get on the question posed here. Additional and more 
extensive data will need to be borrowed from other ﬁ  elds, 
mostly from the ﬁ  eld of solid organ transplantation.
Data from the fi  eld of solid organ transplantation
When data are borrowed from the ﬁ   eld of transplan-
tation, the main limitation is that, given the combination 
treatment of immunosuppressants, it is usually very 
diﬃ     cult to determine which speciﬁ   c drug (if any) is 
responsible for cancer recurrence. Th  is very intensive 
immuno  suppression, in combination with the absence of 
an underlying autoimmune disease, makes the translation 
of transplant data to the rheumatologic ﬁ  eld  very 
diﬃ   cult. Aware of these limitations, we will brieﬂ  y look at 
the major ﬁ  ndings from these studies and general conclu-
sions that might be drawn for rheumatic patients.
A relapse rate of 21% was reported in a retrospective 
analysis of 1,137 malignancy patients who received a 
renal graft [53]. In regard to cancer type, the highest 
recurrence rates occurred with multiple myeloma (67%), 
non-melanoma skin cancers (53%), sarcomas (29%), 
bladder cancer (29%), symptomatic renal tumors (27%), 
and breast cancer (23%). In regard to timing of immuno-
suppres  sion, most recurrences (35%) were seen in 
patients who were treated for a malignant disease within 
2 years prior to transplantation. In those treated 2 to 
5 years or more than 5 years before transplantation, 33% 
and 13% relapses were diagnosed, respectively (Figure 3).
In a study of 939 patients treated for cancer prior to 
transplantation, 185 (22%) showed cancer recurrence, 
and 53% of relapses occurred in patients treated within 
2  years before trans  plan  tation [54]. Table  1  gives an 
overview of which cancers had shown a low, an 
intermediate, or a high risk of relapse.
Current guidelines for the clinical management of 
transplant patients indicate a prompt reduction or dis-
con  tinuation of immunosuppressive drugs once the post-
transplant malignancy is diagnosed [55-59]. Th  e  obvious 
downside is that such a strategy may precipitate allograft 
rejection and graft failure. Th  e higher incidence of 
relapses following immunosuppression therefore has led 
to the recommendation of a 2-year waiting period between 
(successful) cancer treatment and organ transplantation 
[53,54,60-62]. Nevertheless, the 2-year waiting period 
might be justiﬁ   ed for most malignancies, whereas for 
carcinoma in situ, low-grade bladder, and basal cell skin 
tumors, no waiting period is necessary. On the other 
hand, longer waiting periods (of over 24 months) are 
needed for other malignancies, such as melanoma, breast 
cancer, and colo  rectal cancer. For lymphomas, a waiting 
period of approxi  mately 5 years is desirable [53,54,60-62].
Risk stratifi  cation of considerations
Type and prognosis of malignancy
According to the World Health Organization deﬁ  nition, 
tumors can be categorized regarding their potential 
curability into ﬁ  ve categories; examples for each are given 
in Table 1. Th  is system can be an initial guidance for 
evaluation of the malignant potential of the cancer that 
has been treated, although these categories only roughly 
reﬂ  ect prognosis. Th   e EUROCARE-4 (European Cancer 
Registry-Based Study on Survival and Care of Cancer 
Patients) Working Group published mean age-adjusted 
5-year survival data for patients whose cancer was 
diagnosed between 2000 and 2002 [63]; the results are 
also shown in Table 1.
Quality of cancer care
In general, the survival of patients depends on many 
additional aspects that are not considered if only survival 
rates are presented. Th   e quality of care – as reﬂ  ected in 
eﬀ  ective programs on prevention and screening, access 
to diagnostic and treatment facilities, tumor-site-speciﬁ  c 
protocols, multidisciplinary management, application of 
evidence-based clinical guidelines, and recruitment to 
clinical trials – considerably inﬂ  uences the outcome and 
survival of patients with cancer. Th   is may explain, in part, 
the considerable regional diﬀ  erences that can be noted in 
cancer survival, but diﬀ  erences in populations also likely 
play a role here [63,64].
Burden of disease and remission of malignancy
Regardless of the type and prognosis of a tumor, assess-
ments of the current stage of tumor burden (presence of 
remission) or its change (response) have to be evaluated. 
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a malignant disease in remission; conceptually, this would 
be the earliest time point at which a patient with a history 
of cancer could reasonably safely be treated with an 
immuno  suppressive drug. Th  e term ‘remission’ implies 
that the disease has been either eliminated or substan-
tially reduced. Th   e RECIST (Response Evaluation Criteria 
In Solid Tumors) criteria, a classiﬁ  cation system that was 
published in 2009, may be used for that purpose [65]. Th  e 
evaluation of response status is performed at the end of a 
treatment period and includes results from clinical 
examination, imaging techniques, and speciﬁ  c lab tests. 
Th  e RECIST system deﬁ  nes complete remission, partial 
remission, stable disease, and progressive disease. Given 
the lack of evidence on the risk of cancer relapse by stage, 
a complete remission seems to be a reasonable pre-
requisite before the initialization of immunosuppressive 
treatment is considered. For accurate classiﬁ  cation 
accord  ing to the RECIST system, consultation with an 
oncologist would be useful.
Special clinical situations
Rheumatic conditions as a consequence of cancer therapy
Th  ere is evidence that chemotherapy for malignant 
diseases may induce rheumatic diseases [66-70] (Figure 1, 
arrow 5); in such a case, the primary treatment would be 
the discontinuation of the culprit agent if this is possible. 
However, it is conceivable that classical anti-rheumatic 
treatment approaches may also need to be considered in 
some of these patients; in that case, all considerations 
made so far would apply.
Post-transplant lymphoproliferative disorder
PTLD covers a disease spectrum ranging from infectious 
mononucleosis to malignant lymphoma, and although by 
deﬁ  nition PLTD occurs in transplant patients, the likely 
cause is the combined immunosuppressive treatment 
rather than the fact that an organ has been transplanted. 
Early polymorphic lymphomas, which are Epstein-Barr 
virus (EBV)-positive, respond well to the reduction of 
immunosuppression. In contrast, EBV-negative, mono-
morphic types are unresponsive to the reduction of 
immuno  suppression and have a poorer prognosis. As 
many of the rheumatic conditions per se put patients at 
risk for lymphoproliferative disease, this might even be 
the case when there is no history of malignant disease.
Suggested management
A challenge faced in this review is the lack of direct 
evidence that could be used to advise physicians on how 
to proceed in the clinical situation of a cancer patient 
with a rheumatic condition requiring immunosuppressive 
treatment. Th  us, only circumstantial evidence can be 
used to infer a strategic approach. Th   is includes data on 
the frequency of new-onset malignancy,  the potential 
treatments that may be used, data on the malignant 
potential of diﬀ  erent tumors, and (of course) data from 
other ﬁ   elds in which immunosuppressive agents are 
employed more commonly and in which similar clinical 
questions have been raised.
On the basis of these data, a very generic stepwise 
approach to the problem can be taken as suggested in 
Figure 4. Th  e ﬁ  rst step obviously is to recognize the 
Figure 3. Risk of cancer relapse from solid organ transplantation according to time between cancer treatment and transplantation 
(adapted from Penn, 1993, black bars [54] and Penn, 1997, gray bars [53]). The data from 1997, with longer follow-up period and higher 
patient number, lead to the recommendation of longer waiting time between tumor treatment and transplantation in graft recipients with pre-
existing malignancies.
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malignant diseases in the past in every patient 
considered for immunosuppressive therapy). In case of 
a currently active/ongoing malignancy, it should be 
considered whether the rheumatic disease to be treated 
is of paraneoplastic or tumor-associated pathogenesis, 
in which case the treatment of the malignancy is the 
ﬁ   rst therapeutic step. Alternatively, a therapeutic 
regimen that has been used for treatment of the 
malignant disease may be the cause of the rheumatic 
complaints; in that case, discontinuation and change of 
regimen would be the optimal approach. Of note, some 
of the chemo  therapy-related rheumatic disorders may 
not appear until as much as 1 year after cytotoxic 
therapy. However, these conditions, if not related to 
neoplasm relapse, usually disappear without additional 
therapy.
If neither the ongoing malignancy nor its treatment can 
be attributed as the cause of the rheumatic condition 
(that is, the rheumatic and oncologic diseases are 
independent), a consultation with an oncologist will be 
required before any immunosup  pressive/DMARD treat-
ment can be employed. It is likely that the patient will be 
considered ineligible for such treatment and that only 
symptomatic therapy can be used.
In case of the absence of an active malignant disease but 
a positive history of such a disease, the prevailing disease 
status needs to be evaluated. As the initial step here, the 
Table 1. Survival and characteristics of cancer 
  European average  Tumor category  Risk of relapseb  Recurrence rate after
Tumor site  5-year survival [63,64]  (WHO)a [53,54,59-61]  transplantation  [53,54,59-61]
Pancreas 5.7%  5  -  -
Liver 9.1%  2  -  -
Esophagus 11.1%  3  -  -
Lung 12.0%  3  -  -
Gallbladder and biliary tract  14.4%  5  -  -
Brain 19.7%    -  -
Stomach 24.5%  3  -  -
Multiple myeloma  35.1%    +++  >25%
Ovary and uterine adnexa  36.5%  2  -  -
Head and neck  39.5%  3  -  -
All leukemias  42.4%  1 and 3  -  -
NHL  51.5%  1  +  Up to 10%
Colorectal 54.0%  2  ++  11%-25%
Bone and cartilage  55.5%  3  +++  >25%
Kidney 58.0%    +++  >25%
Soft tissue sarcoma  59.5%  2  +++  >25%
Cervix uteri  62.6%  3  +  Up to 10%
Bladder 72.4%  3  +++  >25%
Larynx 62.8%  4   
Corpus uteri  76.2%  3  ++  11%-25%
Prostate 76.4%  3  ++  11%-25%
Breast 79.4%  2  ++  11%-25%
Hodgkin  80.1%  1  +  Up to 10%
Melanoma of skin  82.6%  5  +++  >25%
Thyroid  82.9%  5  +  Up to 10%
Testis  89.5%  1  +  Up to 10%
aCategory 1: These tumors are characterized by their principal curability; that is, the use of single or combination drug therapy will result in the cure of at least some 
patients. Category 2: For these cancers, the survival is prolonged when adjuvant chemotherapy is used with surgery or radiotherapy in the early stages. Category 3: 
These are neoplasms, for which there is evidence that the use of a single drug or combination of drugs will cause tumor shrinkage and possibly improve quality of 
life; survival may be prolonged but this may be of short duration. Category 4: The local control of these malignancies may be improved by the use of chemotherapy 
before, during, or after surgery or radiotherapy. Category 5: These are tumors for which there are currently no eff  ective drugs. bRisk of relapse is categorized as low (+), 
intermediate (++), or high (+++). NHL, non-Hodgkin lymphoma; WHO, World Health Organization.
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Page 7 of 11task is to determine the duration of complete remission 
(that is, the recovery from all evidence of disease). On the 
basis of the transplant literature and the scarce data from 
registries on rheumatic diseases, 2 years seem to be the 
minimum requirement for cancers with low to inter-
mediate risk of relapse, whereas those with a high risk of 
relapse should likely be handled similarly to patients with 
an active/ongoing malignant disease (Figure 4).
Once the decision of using an immunosuppressive 
agent is an option in a given patient, the choice of drug is 
the next decision to be made. Th  is decision will be a 
combined evaluation of the risk of relapse on the basis of 
the cancer type and the length of remission as well as the 
tumorigenic potential of the drug to be used (as brieﬂ  y 
reviewed above). An interdisciplinary conference with an 
experienced oncologist is still advisable.
Especially when considering data from the transplan  ta-
tion literature, however, the fact that usually a combi-
nation therapy of multiple drugs is employed should be 
considered before risks are attributed to individual drugs. 
For example, it remains unclear whether monotherapy of 
glucocorticoids, calcineurin inhibitors, or anti-metabo-
lites are aﬄ   icted with an increased cancer risk. In fact, 
outside the transplantation literature, there is no solid 
evidence for such a risk after exposure to each of these 
regimens individually. Exceptions to this are likely the 
alkylating agents, which seem to increase hematologic 
malignancy risk, and (in particular) cyclophosphamide, 
which increases the incidence of bladder cancer. In any 
case, it needs to be emphasized again that the direct 
evidence investigating the risk of anti-rheumatic treat-
ment in patients with a history of malignancy is sparse.
Figure 4. Algorithm for the management of patients with a rheumatic condition requiring anti-rheumatic (immunosuppressive) 
treatment in the context of a current or past malignancy. A detailed description of the algorithm is presented in the ‘Suggested management’ 
section. *The term ‘remission’ implies that the disease has been either eliminated or substantially reduced; the RECIST (Response Evaluation Criteria 
In Solid Tumors) criteria may be used for the evaluation of remission [65]. **Risk-of-relapse categories are based on Penn [53]: low risk (0% to 10%) 
for testicular cancer, uterine cervical cancer, incidental renal cancer, lymphoma, and thyroid cancer; intermediate risk (11% to 25%) for corpus 
uteri, Wilms’ tumor, colon cancer, prostate cancer, and breast cancer; and high risk (>25%) for bladder cancer, renal cancer, sarcoma, skin cancer 
(melanoma and non-melanomatous), and multiple myeloma.
Malignant disease in 
remission* >2years?
NO
Is the rheumatic disease
paraneoplastic?
YES
Is the rheumatic disease caused by
the treatment of malignancy?
NO
Treat the
malignancy
YES
 Consultation of oncologist
required
 Strictest indication of
immunosuppressive treatment
 Consider symptomatic treatment
and/or longer waiting time
NO
 Consider changing
antineoplastic treatment
(together with oncologist)
 Symptomatic treatment of
rheumatic disease if
possible
YES
YES NO
Current malignant disease?
NO YES
High risk of relapse?**
 Consultation of oncologist
recommended
 Use of immunosuppressive
drugs possible according to
 drug type, 
 cancer type, and
 duration of remission
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Page 8 of 11Th  e most commonly ‘required’ anti-rheumatic treat-
ments, however, are methotrexate and probably the bio-
logi  cal response modiﬁ  ers, especially the TNF inhibitors. 
In regard to the risk of malignancy following metho-
trexate, the literature is very favorable, demonstrating a 
low lymphoma incidence in almost a million exposed 
patients, although some cases of PTLD-like syndrome 
were seen. For this reason, methotrexate seems to be a 
drug with a safe proﬁ  le. Similarly, TNF inhibitors have a 
very favorable risk proﬁ  le in regard to cancer develop-
ment on the basis of exposure of thousands of patients 
with RA, although TNF inhibitors may accelerate the 
diagnosis of cancer in the ﬁ  rst 6 to 12 months of treat-
ment. According to some reports, TNF inhibitors may 
even decrease the risk of colorectal and breast cancer in 
patients with RA. However, on the basis of the available 
literature, it would be advisable to be cautious with 
combined immunosuppressive treatment in patients with 
a history of cancer.
In selected cases, less commonly used drugs, given 
their relatively good data indicating even lower cancer 
rates, may be used in patients with a history of cancer. 
Th   ese include mycophenolate mofetil, which has shown a 
signiﬁ  cant and substantial risk reduction of PTLD-like 
disorder as well as a lower risk of malignancy in general. 
Th  e mTOR inhibitors, with their impressive anti-onco-
genic properties, may be considered to be alternative 
immunosuppressives in special clinical situations.
Conclusions
In summary, if patients with a history of cancer are 
exposed to immunosuppressive drugs, regular and 
frequent monitoring is certainly an essential requirement. 
Th  is may include the use of relevant tumor markers or 
more frequent staging examinations. After all of the 
considerations about the risk of cancer recurrence and 
the tumorigenic potential of the drug to be employed, 
one important aspect should not be overlooked, namely 
the potential undertreatment of the rheumatic condition, 
which might lead to a reduction in quality of life or, 
potentially even more than the underlying malignant 
disease in some instances, might be a threat to life itself.
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